Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary <i>Mycobacterium kansasii</i>
Shashikant Srivastava, Jann‐Yuan Wang, Gesham Magombedze, Moti Chapagain, Hung‐Ling Huang, Devyani Deshpande, Scott K. Heysell, Jotam G. Pasipanodya, et al. (9 authors)
Antimicrobial Agents and Chemotherapy · 2021-02
Abstract
Standard therapy (isoniazid, rifampin, and ethambutol), with or without a macrolide, for pulmonary Mycobacterium kansasii lasts more than a year. Therefore, shorter treatment duration regimens are required.
MeSH terms
- Mycobacterium kansasii
- Ethambutol
- Isoniazid
- Medicine
- Mycobacterium tuberculosis
- Microbiology